- Home
- SGMT vs GNLX Comparison
SGMT vs GNLX Comparison
Compare SGMT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | GNLX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.7M | 202.4M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SGMT | GNLX |
|---|---|---|
| Price | $6.33 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $29.75 | $19.75 |
| AVG Volume (30 Days) | ★ 541.5K | 194.5K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.73 | $1.99 |
| 52 Week High | $11.41 | $8.54 |
Technical Indicators
Market Signals| Indicator | SGMT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 36.73 |
| Support Level | $5.95 | $4.37 |
| Resistance Level | $6.58 | $5.02 |
| Average True Range (ATR) | 0.39 | 0.43 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 28.46 | 1.97 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.